Bloomberg -- Dendreon Corp. rose the most in two years in Nasdaq trading after the company reserved conference space to present data on its prostate cancer drug later this month.
Bloomberg -- Dendreon Corp. rose the most in two years in Nasdaq trading after the company reserved conference space to present data on its prostate cancer drug later this month.